While NSD2 was either not expressed or expressed at low levels in the non-lethal tumors, its expression increased dramatically in advanced disease stages and was particularly robust in the most aggressive phenotypes, namely CRPC adenocarcinomas and NEPC (p < 0.01, two-tailed Fisher's exact test; Fig. 4e). The gene discussed is NSD2; the disease is adenocarcinoma.